Related Products
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
GLOW 70mg
70mg
Related Research News
Pharmacy Guidance on GLP-1s and Compounded Peptide Therapies
Pharmacy Times published guidance for pharmacists on counseling patients about GLP-1 receptor agonists and compounded peptide therapies. The article covers what patients want to know about these treatments, including safety, efficacy, and regulatory considerations.
FDA Moves to Restrict Bulk Compounding of Novo, Lilly Weight-Loss Drugs
The FDA plans to limit bulk compounding of weight-loss drugs from Novo and Lilly. This action targets practices involving these popular medications. Regulators aim to control how such drugs are produced in large quantities by compounding pharmacies.
FDA Proposes Ban on Bulk Compounding of Semaglutide and Tirzepatide
The U.S. Food and Drug Administration has proposed a ban on bulk compounding of semaglutide and tirzepatide. This regulatory proposal names semaglutide and tirzepatide as the drugs subject to the ban. The action focuses on prohibiting bulk compounding for these two medications.